Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 1, 2000, Pages 71-79

  DeNardo, Sally J ^a   Burke, Patricia A ^a   Leigh, Bryan R ^a   O'Donnell, Robert T ^a   Miers, Laird A ^a   Kroger, Linda A ^a   Goodman, Simon L ^b   Matzku, Siegfried ^b   Jonczyk, Alfred ^c   Lamborn, Kathleen R ^a   DeNardo, Gerald L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MERCK KGAA   (Germany)

^c Department of Medicinal Chemistry ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; INDIUM 111; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR VASCULARIZATION;

EID: 0033976335     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.71     Document Type: Article

References (44)

1. Varner J, Cheson D. Tumor angiogenesis and the role of vascular cell integrin ανβ3. Important Adv in Oncol 1996;1:69.
2. Cheresh DA. Integrins: structure, function and biological properties. Adv Mol Cell Biol 1993;6:225.
3. Ruoslahti E, Pierschbacher M. Arg-Gly-Asp: a versatile cell recognition sequence. Cell 1986;44:517.
4. Brooks P, Clarke AR, Cheresh D. Requirement of vascular integrin alpha ν beta for angiogenesis. Sci 1994;264:569.
5. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin ανβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815.
6. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ, De Waal RM. Immunohistochemical analysis of integrin ανβ3 expression on tumor-associated vessels of human carcinomas [published erratum appears in Int J Cancer 1997 Aug 7;72(4):706-7]. Int J Cancer 1997;71:320.
7. Wong A, Hwang S, McDevitt P, Stadel J, Johanson K. Studies on ανβ3/ligand interactions using a [3H]SK&F-107260 binding assay. Mol Pharmacol 1998;50:529.
8. Varner J, Emerson D, Juliano R. Integrin α5β1 expression negatively regulates cell growth:reversal by attachment to fibronectin. Mol Cell Biol 1994;7:725.
9. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alpha Vbeta3 during angiogenesis. J Clin Invest 1996;98:426.
10. Montgomery A, Reisfeld RA, Cheresh DA. Integrin ανβ3 rescues melanoma cells from apoptosis in a three dimensional dermal collagen. Proc Natl Acad Sci USA 1994;91:8856.
11. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin ανβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79: 1157.
12. Dechantsreiter MA, Plankar E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL, Kessler H. N-methylated cyclic RGD peptides as highly active and selective ανβ3 integrin antagonists. J Med Chem 1999;42:3033.
13. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Letters 1991;291:50.
14. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R. Conformation/activity studies of rationally designed potent anti-adhesion RGD peptides. Eur J Biochem 1992;210:911.
15. Muller G, Gurrath M, Kessler H, Timpl R. Dynamic forcing, a method for evaluating activity and selectivity profiles of RGD peptides. Angew Chem Int Ed Engl 1992;31:326.
16. Liu AY, Robinson RR, Hellstrom KE, Murray EDJ, Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 1987;84:3439.
17. Fell HP, Gayle MA, Yelton D, Lipsich L, Schieven GL, Marken JS, Aruffo A, Hellstrom KE, Hellstrom I, Bajorath J. Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. J Biol Chem 1992;267:15552.
18. Howell LP, DeNardo SJ, Levy N, Lund J, DeNardo GL. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int J Biol Markers 1995;10:126.
19. Winthrop MD, DeNardo SJ, Muenzer JT, Chi SG, Gumerlock PH. p53-independent response of a human breast cancer xenograft to radioimmunotherapy. Cancer 1997;80 Suppl:2706.
20. Li M, Meares CF. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjug Chem 1993;4:275.
21. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984;142:68.
22. DeNardo SJ, Zhong G-R, Salako Q, Li M, DeNardo GL, Meares CF. Pharmacokinetics of chimeric L6 conjugated to indium-111 and yttrium-90-DOTA-peptide in tumor bearing mice. J Nucl Med 1995;36:829.
23. Beaumier PL, Neuzil D, Yang HM, Noll EA, Kishore R, Eary JF, Krohn KA, Nelp WB, Hellstrom KE, Hellstrom I. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J Nucl Med 1986;27:824.
24. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD containing cyclic pentapeptides as highly potent and selective integrin ανβ3 antagonists. J Am Chem Soc 1996;118:7461.
25. Mitjans F, Sander D, Adan J, Sutter A, Martinez JM, Jaggle C-S, Moyano JM, Kreysch H-G, Piulats J, Goodman SL. An anti-av-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995;108:2825.
26. Kraft S, Diefenbach B, Mehta R, Jonczyk A, Luckenbach GA, Goodman SL. Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J Biol Chem 1999;274:1979.
27. Filardo EJ, Brooks PC, Deming SL, Damsky C, Cheresh DA. Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol 1995; 130:441.
28. Goodman SL, Deutzmann R, von der Mark K. Two distinct cell-binding domains in laminin can independently promote nonneuronal cell adhesion and spreading. J Cell Biol 1987;105:589.
29. DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako QA, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, et al. Comparison of DOTA-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2IT-BAD-ChL6 in breast cancer xenografts. Clin Cancer Res 1998;4:2483.
30. Miller RG. Simultaneous Statistical Interference. 2nd ed. New York: Springer-Verlag; 1980; 48.
31. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: Wiley; 1973;
32. DeNardo SJ, Kroger LA, DeNardo GL. A new era for radiolabeled antibodies in cancer? Current Opin Immunol 1999;11:563.
33. Goldenberg DM.New developments in monoclonal antibodies for cancer detection and therapy. CA Cancer J Clin 1994;44:43.
34. DeNardo SJ, Mirick GR, Kroger LA, O'Grady LF, Erickson KL, Yuan A, Lamborn KR, Hellstrom I, Hellstrom KE, DeNardo GL. The biologic window for chimeric L6 radioimmunotherapy. Cancer 1994;73 Suppl:1023.
35. DeNardo SJ, O'Grady LF, Richman CM, DeNardo GL. Overview of radioimmunotherapy in advanced breast cancer using 1-131 chimeric L6. In:Antigen and antibody molecular engineering in breast cancer diagnosis and treatment Ceriani RL(ed) Plenum Press: New York, 1994, 203.
36. Warhoe KA, DeNardo SJ, Wolkov HB, Doggett EC, Kroger LA, Lamborn KR, DeNardo GL. Evidence for external beam irradiation enhancement of radiolabeled monoclonal antibody uptake in breast cancer. Antibody Immunoconj Radiophar 1992;5:227.
37. Srivastava SC, Schlom J, Raubitschek AL, et al. Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 1989;16:721.
38. Humm JL, Ruan S, Larson SM, et al. Optimizing combination therapy with radiolabeled antibodies and external beam. [Abstract] J Nucl Med 1999;40:39P
39. DeNardo GL, DeNardo SJ, Lamborn KR, VanHoosear KA, Kroger LA. Enhancement of tumor uptake of monoclonal antibody in nude mice with PEG IL-2. Antibody Immunoconj Radiophar 1991;4:859.
40. 67Cu-2IT-BAT-Lym-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2. Cancer 1997;80 Suppl:2576.
41. Kessler H, Diefenbach B, Finsinger D, Geyer A, Gurrath M, Goodman SL, Holzemann G, Haubner R, Jonczyk A, Muller G, et al. Design of superactive and selective integrin receptor antagonists containing the RGD sequence. Lett Pept Sci 1995;2:155.
42. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin ανβ3 antagonists. J Am Chem Soc 1996;118:7461.
43. Wermuth J, Goodman SL, Jonczyk A, Kessler H. Stereoisomerism and biological activity of the selective and superactive ανβ3 integrin inhibitor cyclo-(-RGDfV-) and its retroinverso peptide. J Am Chem Soc 1997;119:1328.
44. v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci USA 1999;96: 1591.